Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Heidelberg, Germany, February 28, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. (ET) in Boston.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
